Search citation statements
Paper Sections
Citation Types
Year Published
Publication Types
Relationship
Authors
Journals
Purpose The effectiveness of current follow-up guidelines after breast cancer treatment is uncertain. Tailored surveillance based on patient age and tumor characteristics may be more adequate. This study aimed to analyze the frequency and risk factors for detecting ipsilateral locoregional recurrences (LR) and second primary breast cancers (SP) outside of scheduled surveillance in patients with recurrent breast cancer. Methods Patients with surgically treated early-stage breast cancer from the Malmö Diet and Cancer Study (MDCS), 1991–2014 (n = 1080), and the Västernorrland region, 2009–2018 (n = 1648), were included. Clinical and pathological information on the primary tumor and recurrences was retrieved from medical records. The mode of recurrence detection was defined as detection within (planned) or outside (symptomatic) of scheduled surveillance. Results The median follow-up was 6.5 years. Overall, 461 patients experienced a recurrence. The most common initial event was distant metastasis (47%), followed by locoregional recurrence (LR) (22%) and second primary (SP) (18%). Fifty-six percent of LR and 28% of SP were identified outside of scheduled surveillance. Logistic regression analysis revealed that younger age (under 50 years) (OR 2.57, 95% CI 1.04–6.88), lymph node-positive breast cancer (OR 2.20, 95% CI 1.03–4.87) and breast cancer of the HER2 positive subtype (OR 5.24, 95% CI 1.40–25.90) were correlated with higher odds of detecting a recurrence outside of planned surveillance. Conclusion Most recurrent events were detected outside of scheduled surveillance, particularly for locoregional recurrences. Risk-based surveillance, which takes into account patient and tumor characteristics, might be more suitable for specific patient subsets.
Purpose The effectiveness of current follow-up guidelines after breast cancer treatment is uncertain. Tailored surveillance based on patient age and tumor characteristics may be more adequate. This study aimed to analyze the frequency and risk factors for detecting ipsilateral locoregional recurrences (LR) and second primary breast cancers (SP) outside of scheduled surveillance in patients with recurrent breast cancer. Methods Patients with surgically treated early-stage breast cancer from the Malmö Diet and Cancer Study (MDCS), 1991–2014 (n = 1080), and the Västernorrland region, 2009–2018 (n = 1648), were included. Clinical and pathological information on the primary tumor and recurrences was retrieved from medical records. The mode of recurrence detection was defined as detection within (planned) or outside (symptomatic) of scheduled surveillance. Results The median follow-up was 6.5 years. Overall, 461 patients experienced a recurrence. The most common initial event was distant metastasis (47%), followed by locoregional recurrence (LR) (22%) and second primary (SP) (18%). Fifty-six percent of LR and 28% of SP were identified outside of scheduled surveillance. Logistic regression analysis revealed that younger age (under 50 years) (OR 2.57, 95% CI 1.04–6.88), lymph node-positive breast cancer (OR 2.20, 95% CI 1.03–4.87) and breast cancer of the HER2 positive subtype (OR 5.24, 95% CI 1.40–25.90) were correlated with higher odds of detecting a recurrence outside of planned surveillance. Conclusion Most recurrent events were detected outside of scheduled surveillance, particularly for locoregional recurrences. Risk-based surveillance, which takes into account patient and tumor characteristics, might be more suitable for specific patient subsets.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
customersupport@researchsolutions.com
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.